Birgitta Versluijs

51 Association between respiratory virus and alloimmune lung syndromes TABLE 3. Univariate analysis of predictors for alloimmune mediated lung syndromes. Allo-LS Total N % HR 95% CI P Overall 110 30 27.3 Age 0.95 0.88-1.02 .18 Sex  Male  Female 58 52 15 15 25.9 28.8 1 1.03 0.5-2.12 .93 Indication for HSCT  Malignant disorder  Nonmalignant disorder 56 54 10 20 18.0 35.7 1 2.67 0.87-3.97 .11 HLA disparity  Matched  Mismatched 69 41 17 13 24.6 31.7 1 1.14 2 0.55-2.36 .7 Conditioning  TBI-based  Chemotherapy-based 33 77 4 26 12.1 34.0 1 3.05 1.06-8.75 .04 Donor  Family  Unrelated 33 67 9 21 27.3 31.3 1 1.07 0.49-2.35 .80 Stem cell source  BM/PBSC  CB 67 33 17 13 25.4 39.4 1 2.13 1.03-4.41 .042 RV infection  No  Yes 55 55 3 27 6.7 52.9 1 10.3 3.14-34.3 .00 Recipient CMV serology  Serology-negative 76 19 25 1  Serology-postive 76 34 19 11 25 32.4 1 1.41 0.59-4.78 .68 HSCT indicates hematopoietic stem cell transplantation; TBI, total body irradiation; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; CMV, cytomegalovirus; Allo-LS, alloimmune mediated lung syndromes 3